Leerink Partnrs Has Negative Outlook of EW FY2025 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Edwards Lifesciences in a report released on Wednesday, February 12th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $2.41 per share for the year, down from their prior forecast of $2.43. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.76 EPS and FY2027 earnings at $3.23 EPS.

A number of other analysts have also commented on EW. Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $79.86.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.83 on Thursday. The company has a market capitalization of $44.72 billion, a PE ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average price is $72.51 and its 200-day moving average price is $69.36. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $610,895,000. Jennison Associates LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $555,939,000. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after buying an additional 3,506,886 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.